Benserazide

Benserazide

File:Benserazide.svg
Gene therapy
Clinical data
Pregnancy category	AU: B3
Physiological data
Legal status
Legal status	UK: POM (Prescription only) (with levodopa)
Pharmacokinetic data
Excretion	Renal and fecal
Identifiers
IUPAC name 2-amino-3-hydroxy-N'-[(2,3,4-trihydroxyphenyl) methyl]propanehydrazide
CAS Number	14919-77-8
PubChem Template:Abbreviation	2327
Chemical and physical data
Formula	C10H15N3O5
Molar mass	293.71 g/mol

Benserazide is an inhibitor of DOPA decarboxylase that does not enter the central nervous system. It is often given in combination with L-DOPA (levodopa) as Co-Beneldopa (BAN) (e.g. Madopar® by Roche in UK) in the treatment of Parkinson's disease to prevent the conversion of L-DOPA to dopamine in the periphery (due to its molecular size it can not penetrate the blood brain barrier) the amount that reaches the central nervous system and reducing the required dose, and also decreasing side effects due to the presence of dopamine in the system (outside of the central nervous system). It has no antiparkinson actions when given alone.

Template:Pharma-stub